GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (OTCPK:NONOF) » Definitions » Forward PE Ratio

Novo Nordisk A/S (Novo Nordisk A/S) Forward PE Ratio : 38.53 (As of Apr. 26, 2024)


View and export this data going back to . Start your Free Trial

What is Novo Nordisk A/S Forward PE Ratio?

Novo Nordisk A/S's Forward PE Ratio for today is 38.53.

Novo Nordisk A/S's PE Ratio without NRI for today is 46.28.

Novo Nordisk A/S's PE Ratio for today is 46.28.


Novo Nordisk A/S Forward PE Ratio Historical Data

The historical data trend for Novo Nordisk A/S's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Forward PE Ratio Chart

Novo Nordisk A/S Annual Data
Trend 2015-12 2016-12 2017-12 2018-12 2019-12 2020-12 2021-12 2022-12 2023-12 2024-04
Forward PE Ratio
25.13 15.95 20.00 17.70 21.05 22.68 33.33 30.40 31.25 37.31

Novo Nordisk A/S Quarterly Data
2015-12 2016-03 2016-06 2016-09 2016-12 2017-03 2017-06 2017-09 2017-12 2018-03 2018-06 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03 2020-06 2020-09 2020-12 2021-03 2021-06 2021-09 2021-12 2022-03 2022-06 2022-09 2022-12 2023-03 2023-06 2023-09 2023-12 2024-03
Forward PE Ratio 25.13 21.37 21.88 16.03 15.95 15.58 17.64 18.45 20.00 19.08 18.94 18.32 17.70 21.05 20.75 18.73 21.05 21.46 25.06 23.04 22.68 22.57 26.81 30.40 33.33 32.36 32.47 25.64 30.40 34.84 31.65 31.65 31.25 37.74

Competitive Comparison of Novo Nordisk A/S's Forward PE Ratio

For the Biotechnology subindustry, Novo Nordisk A/S's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Forward PE Ratio falls into.



Novo Nordisk A/S Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Novo Nordisk A/S  (OTCPK:NONOF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Novo Nordisk A/S Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.